Higher levels of IL‐6 early after tocilizumab distinguish survivors from nonsurvivors in COVID‐19 pneumonia: A possible indication for deeper targeting of IL‐6
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Higher levels of IL‐6 early after tocilizumab distinguish survivors from nonsurvivors in COVID‐19 pneumonia: A possible indication for deeper targeting of IL‐6
Authors
Keywords
-
Journal
JOURNAL OF MEDICAL VIROLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-06-09
DOI
10.1002/jmv.26149
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
- (2020) Paola Toniati et al. AUTOIMMUNITY REVIEWS
- Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease
- (2020) Emanuele Pontali et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care
- (2020) Luca Quartuccio et al. JOURNAL OF CLINICAL VIROLOGY
- Tocilizumab treatment in COVID-19: A single center experience
- (2020) Pan Luo et al. JOURNAL OF MEDICAL VIROLOGY
- Clinical Outcomes in COVID‐19 Patients Treated with Tocilizumab: An Individual Patient Data Systematic Review
- (2020) Daniel Antwi‐Amoabeng et al. JOURNAL OF MEDICAL VIROLOGY
- COVID‐19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS‐CoV‐2 infected patients
- (2020) Chiranjib Chakraborty et al. JOURNAL OF MEDICAL VIROLOGY
- Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study
- (2020) Matthew J Cummings et al. LANCET
- COVID-19: consider cytokine storm syndromes and immunosuppression
- (2020) Puja Mehta et al. LANCET
- Comparison of infection-related hospitalization risk and costs in tumor necrosis factor inhibitor-experienced patients with rheumatoid arthritis (RA) treated with abatacept or other targeted disease-modifying anti-rheumatic drugs (tDMARDs)
- (2020) Damemarie Paul et al. JOURNAL OF MEDICAL ECONOMICS
- The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease
- (2020) Dennis McGonagle et al. AUTOIMMUNITY REVIEWS
- Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
- (2019) Lara L. Riegler et al. Therapeutics and Clinical Risk Management
- Comparison of the clinical characteristics and severity of community-acquired pneumonia between patients with rheumatoid arthritis treated with tocilizumab and those treated with TNF inhibitor
- (2018) Yoshiki Nagai et al. Modern Rheumatology
- Proinflammatory Cytokines, Aging, and Age-Related Diseases
- (2013) Martin Michaud et al. Journal of the American Medical Directors Association
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now